Free Newsletter
SPOTLIGHT: FDA gives nod to new Plavix dose
Sanofi-Aventis and Bristol-Myers Squibb announced that they'd nabbed FDA approval for a new 300 mg strength of the anti-clotting drug Plavix, for use as a loading dose when heart patients come into the ER. Release
More stories about FDA approval
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: